Niagen Bioscience Q2 Miss: Sales Slip, Profits Collapse, and Legal Clouds Gather
NAGE is trading near its 52-week low of $3.115 (3.4% above the low).
Summary
Niagen Bioscience missed Q2 revenue estimates and saw profits collapse as ingredient sales slumped and marketing costs surged. The company also disclosed a potential $10.4M litigation liability and new class action lawsuits, partially offset by regulatory milestones for its rare disease drug candidate.
Key Events · Earnings and Guidance · NAGE
-
Q2 Revenue Miss
Net sales of $29.79M missed the $30.69M consensus, driven by a 29% drop in ingredients segment sales to $5.39M.
-
Profitability Collapse
Net income fell to $963K from $3.61M YoY; operating income dropped to $700K from $3.19M as sales and marketing expenses surged 23% to $10.13M.
-
Elysium Litigation Overhang
The company disclosed a potential $10.4M liability if it loses the appeal of the $9.2M attorneys' fees award in the Elysium patent case; no accrual has been recorded.
-
New Class Action Lawsuits
Two putative class actions were filed in May and June 2026 alleging false or misleading advertising for Tru Niagen; the cases have been consolidated.
Analysis · NAGE · Life Sciences
Niagen Bioscience's Q2 2026 results fell short of expectations, with net sales of $29.79M missing the $30.69M consensus and net income plunging to $963K from $3.61M a year ago. The core ingredients business saw a 29% sales decline, while a 23% jump in sales and marketing spend failed to drive top-line growth. Against this backdrop, the company faces a potential $10.4M liability from the Elysium patent litigation appeal, two new class action lawsuits over Tru Niagen advertising, and a patent challenge from Thorne. On the positive side, the FDA granted Rare Pediatric Disease designation for its lead drug candidate NB4168, and the EMA granted Orphan Medicinal Product Designation. The stock trades near its 52-week low, reflecting the market's dim view of the deteriorating fundamentals and mounting legal risks.
At the time of this filing, NAGE was trading at $3.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.4M. The 52-week trading range was $3.12 to $11.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.